CardioVentures, Inc. (SSI-DE) entered into non-binding letter of intent to acquire AVRA Medical Robotics, Inc. (OTCPK:AVMR) in a reverse merger transaction on August 5, 2022. CardioVentures, Inc. (SSI-DE) entered into a definitive merger agreement to acquire AVRA Medical Robotics, Inc. in a reverse merger transaction on November 7, 2022. In the Merger, holders of the outstanding shares of common stock of SSI-DE at closing, will receive in exchange for their SSI – DE shares, such number of shares of AVRA common stock as will result in such holders owning 95% of the outstanding post-Merger shares of AVRA common stock, with the current shareholders of AVRA owning 5% of the outstanding post-Merger shares of AVRA common stock. In addition, the holders of SSI-DE common stock will receive, pro rata , shares of newly designated Series A Non-Convertible Preferred Stock. The Series A Preferred Shares are not convertible into common stock, do not have any dividend rights and have a nominal liquidation preference. Upon consummation of the merger, the Company (which will change its name to SS Innovations International, Inc.), will acquire an indirect controlling interest in SSI India and ownership of the SSI Intellectual Property and Dr. Srivastava will become the Company's controlling shareholder. Upon consummation of the merger, the Company will change its name to SS Innovations International, Inc. and the stockholders of CardioVentures will become the controlling shareholders of AVRA Medical Robotics. Concurrent with consummation of the Merger, the current directors and executive officers of AVRA will resign, other than Barry Cohen, who will continue as a director and in a new executive capacity, and the designees of the SSI-DE stockholders will be appointed to AVRA's board of directors and management. Immediately after consummation of the Merger, CardioVentures shall issue to Frederic Moll additional number of shares of our common stock in an amount that, when combined with the Initial Company Shares, will equal seven percent (7%) of our then issued and outstanding shares of common stock post-Merger on a fully-diluted basis.

In addition to customary closing conditions, consummation of the Merger is subject to other conditions including AVRA shall have changed its corporate name to “SS Innovations International, Inc."; AVRA shall have implemented a one for ten reverse stock split; and AVRA shall have increased its authorized common stock to 250,000,000 shares; an Employment Agreement between AVRA and Barry Cohen shall have been entered into; the Corporate Notification Form shall have been cleared by FINRA, the current directors and executive officers of AVRA (other than Barry F. Cohen, who shall continue to serve as a director of AVRA after the Effective Time) shall have resigned and other conditions. The Merger Agreement, have been approved by AVRA's board of directors and majority stockholders. The respective Boards of Directors of AVRA and SSI-DE have each unanimously approved this Agreement. The stockholders of SSI-DE determined that this Agreement, the Merger and the other transactions contemplated by this Agreement is advisable, fair to and in the best interests of the stockholders of SSI-DE and has approved this Agreement, the Merger and the other transactions contemplated by this Agreement. As of November 30, 2022, it has filed all required periodic reports with the Securities and Exchange Commission and accordingly is current in its filing SEC status.

Dale S. Bergman of Gutierrez Bergman Boulris, PLLC. acted as legal advisor to AVRA Medical Robotics, Inc. Sara L. Terheggen of The NBD Group, Inc. acted as legal advisor to SSI-DE and Sudhir Srivastava, shareholder of SSI-DE. VStock Transfer, LLC acted as transfer agent to AVRA.

CardioVentures, Inc. (SSI-DE) completed the acquisition of AVRA Medical Robotics, Inc. (OTCPK:AVMR) for $10.9 million in a reverse merger transaction on April 14, 2023. In connection with the closing of the merger, AVRA changed its corporate name to SS Innovations International, Inc. (“SSII”). Pursuant to the Merger Agreement, at Closing, holders of the outstanding shares of common stock of CardioVentures, were issued 135,808,884 shares of SSII common stock, representing approximately 95% of issued and outstanding shares of SSII common stock post-Merger, with the existing shareholders of SSII holding approximately 6,544,344 shares of SSII common stock representing approximately 5% of issued and outstanding shares of SSII common stock post-Merger.